
Alkapac Syrup
MSN LABORATORIES - syrup - 100 ml
Standard delivery
Distributor inventory | Tablet
Medically reviewed by Dr. Balaji Krishnan, MBBS · Updated August 2026
Silodosin (8mg) + Mirabegron (50mg)
Treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) such as weak urine stream, hesitancy, incomplete bladder emptying; management of overactive bladder symptoms (urgency, frequency, urge incontinence) when present along with BPH/LUTS.
Silodosin is a selective alpha-1A adrenergic blocker that relaxes smooth muscle in the prostate and bladder neck to improve urine flow and reduce obstruction symptoms. Mirabegron is a beta-3 adrenergic agonist that relaxes the bladder detrusor during the storage phase, increasing bladder capacity and reducing urgency/frequency.
Take as prescribed by the doctor. Usually taken once daily with food, preferably at the same time each day. Swallow the tablet whole with water; do not crush or chew. If a dose is missed, take it when remembered unless it is close to the next dose; do not double.
Common side effects of Silotrif M 50 Tab may include:

MSN LABORATORIES - syrup - 100 ml
Standard delivery

MSN LABORATORIES - syrup - 450 ml - 450 ml
Standard delivery

MSN LABORATORIES - tablet - 12.5 mg - 4 S
Standard delivery

MSN LABORATORIES - tablet - 4 S
Standard delivery

MSN LABORATORIES - tablet - 10 Tablet
Standard delivery
MSN LABORATORIES - tablet - 10 Tablet
Standard delivery

MSN LABORATORIES - tablet - 10 S
Standard delivery

MSN LABORATORIES - tablet - 10 S
Standard delivery
For men with BPH/LUTS: may cause dizziness/fainting due to low blood pressure—rise slowly and use caution when driving. Mirabegron can increase blood pressure; monitor BP especially in patients with hypertension and avoid/use with caution in severe uncontrolled hypertension. Risk of urinary retention, especially in bladder outlet obstruction and when combined with antimuscarinics—seek help if unable to pass urine. Dose adjustment/caution may be needed in kidney or liver impairment; avoid strong CYP3A4 inhibitors with silodosin in some patients. Tell eye surgeon before cataract/glaucoma surgery (risk of intraoperative floppy iris syndrome with alpha-blockers).